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KAJIAN GENETIK MOLEKUL GEN RESEPTOR PROSTAGLANDIN F2α DI 
KALANGAN PESAKIT GLAUKOMA DI MALAYSIA. 
 
 
ABSTRAK 
 
 
Kesan sampingan yang berpunca daripada dadah antiglaukoma topikal iaitu Latanoprost 
telah banyak dilaporkan. Keberkesanan dadah ini mungkin berbeza bergantung kepada 
setiap individu. Oleh itu, hipotesisnya ialah sebarang perubahan yang berlaku pada 
reseptor prostanoid (FP) iaitu reseptor di mana dadah tersebut akan bertindak, mungkin 
bertanggungjawab dalam mempengaruhi sebarang kepelbagaian keberkesanan dadah 
tersebut dan juga kesan sampingannya. Matlamat kajian ini ialah untuk mengenalpasti 
jenis serta frekuensi polimorfisma yang terdapat pada reseptor prostanoid (FP) di 
kalangan rakyat Malaysia dan kesannya kepada pesakit glaukoma. Tindakbalas berantai 
polimerase (PCR) akan mengamplifikasi ke semua ekson gen reseptor Prostaglandin 
F2α. Variasi atau polimorfisma di dalam gen reseptor Prostaglandin F2α akan disaring 
dengan menggunakan teknik kromatografi cecair denaturasi berprestasi tinggi (dHPLC). 
Mutasi yang dijumpai oleh dHPLC akan disahkan dengan teknik penjujukan DNA. Pada 
masa yang sama, tekanan intraokular (IOP) dan sebarang kesan sampingan pada 
setiap pesakit akan diawasi dalam tempoh 3 bulan. Mutasi telah dijumpai di dalam 2 
daripada 12 bahagian yang mengamplifikasi keempat-empat ekson gen reseptor 
Prostaglandin F2α. Mutasi baru iaitu IVS3 -97A>T telah dijumpai pada 34 orang pesakit 
dan 32 orang kumpulan kawalan dan satu lagi mutasi iaitu EX4 1209A>G telah dijumpai 
pada 23 orang pesakit dan 27 orang kumpulan kawalan setelah 160 orang pesakit dan 
kumpulan kawalan disaring. Kedua-dua polimorfisma nukleotida tunggal (SNP) tersebut 
yang dijumpai di dalam gen reseptor Prostaglandin F2α secara statistiknya tidak 
  
 
xx
mempunyai sebarang kaitan dengan glaukoma dan kesan penurunan IOP di kalangan 
pesakit glaukoma yang menerima latanoprost topikal. Oleh itu, kami percaya bahawa 
bahagian-bahagian lain di dalam gen tersebut penting untuk disaring, selain melibatkan 
saiz sampel yang lebih besar, penglibatan pelbagai institusi serta kajian yang lebih lama 
mungkin diperlukan untuk mengesahkan hubungan di antara polimorfisma di dalam gen 
reseptor prostaglandin F2α dengan kepelbagaian tindak balas pesakit terhadap 
latanoprost.     
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MOLECULAR GENETICS STUDY OF PROSTAGLANDIN F2α RECEPTOR GENE IN 
GLAUCOMATOUS PATIENTS IN MALAYSIA 
 
 
 
ABSTRACT 
 
 
The adverse reaction that arises from topical antiglaucoma drug namely, Latanoprost, 
has already been reported. The effectiveness of the drug may vary according to 
individual. We hypothesize that any changes in the human prostanoid (FP) receptor, the 
receptor to which the drug acts, could be responsible for the variation in the 
effectiveness of the drug as well as the adverse reaction. The objective of this study was 
to identify the types and frequencies of prostaglandin F2α receptor gene polymorphisms 
among the Malaysian population and its implication to the glaucoma patients. 
Polymerase Chain Reaction (PCR) was used to amplify all the four exons of 
prostaglandin F2α receptor gene. The polymorphisms of prostaglandin F2α receptor gene 
was screened by using denaturing High Performance Liquid Chromatography (dHPLC).  
Any mutations detected by dHPLC were then confirmed by DNA sequencing. Intraocular 
pressure (IOP) and any side effects for each of the patients were monitored within three 
months post initiation of latanoprost treatment. Out of the twelve regions that amplified 
from the four exons of prostaglandin F2α receptor gene, two SNPs were found. A novel 
SNP IVS3-97 A>T was found in 34 patients and 32 controls after 160 glaucoma patients 
and controls were screened. Another SNP, EX4 1209 A>G was identified in 23 patients 
and 27 controls among the study subjects. However, both of these SNPs which were 
found within the prostaglandin F2α receptor gene did not show any statistically significant 
association either with glaucoma susceptibility or IOP lowering effect in glaucoma 
patients who received topical latanoprost. Therefore, we believed that larger coverage of 
  
 
xxii
gene to be screened, larger sample size, multicenter and longer period of study is 
perhaps needed to confirm the possible association between polymorphisms of 
prostaglandin F2α receptor gene and the variation of responsiveness of patients to the 
latanoprost. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Glaucoma 
 
Glaucoma is defined as a progressive optic neuropathy with characteristic structural 
damage to the optic nerve, which results in specific visual field defects (Quigley, 1993, 
Kroese et al., 2003). Elevated intraocular pressure (IOP) is the only modifiable risk 
factor, although there are a group of patients who have typical glaucomatous damage of 
the visual fields and/or optic nerve heads despite the IOP being consistently maintained 
at 21 mmHg or less (normal tension glaucoma) (Lewis et al., 1983). Glaucoma is 
generally divided into two major types; angle-closure glaucoma (ACG) and open angle 
glaucoma (OAG). It may also be further divided according to the causes (primary or 
secondary) (Lee, 2000).  
 
Open angle glaucoma (OAG) is the form of glaucoma which occurs in eyes with open 
anterior chamber angles. This form of glaucoma is further classified into primary open 
angle glaucoma (POAG) and its subsets, normal tension glaucoma (NTG) and ocular 
hypertension (OHT). POAG is the most common form of glaucoma and mainly occurs in 
the older age group (older than 40 years old) (Monemi et al., 2005). This type of 
glaucoma is usually defined by three criteria: IOP consistently above 21 mmHg in at 
least one eye, open or normal appearing anterior chamber angle with no apparent ocular 
or systemic abnormality that might account for the elevated IOP and typical 
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glaucomatous visual field and/or optic nerve head damage. One of its subsets, NTG, is a 
condition where the IOP remains within limit (less than 21mmHg) but with the 
occurrence of progressive optic nerve damage and visual field loss (Sowka, 2005). It is 
thought to be related to poor blood flow to the optic nerve, which leads to the death of 
cells which carry impulses from retina to the brain. The other subset, OHT, is usually 
associated with elevated intraocular pressure (>21 mmHg) but normal optic nerve head 
or visual fields (Phelps, 1977). In addition, according to Ocular Hypertension Treatment 
Study (OHTS), OHT was defined as IOP more than 24 mmHg and less than 32 mmHg in 
at least one eye, IOP more than 21 mmHg and less than 32 mmHg in the fellow eye and 
normal visual fields and optic disc in both eyes at the time of diagnosis (Kymes et al., 
2006). 
 
In general, the decrease in peripheral vision which may eventually lead to blindness in 
glaucoma patients is due to the optic nerve damage at the back of the eye. This damage 
is mainly due to the increased pressure in the eye as a result of the excessive 
production of aqueous humor or improper drainage of the aqueous through the outflow 
facilities either by conventional outflow pathway (Trabecular meshwork-Schlemm’s 
canal) or non-conventional outflow (uveoscleral outflow) (Figure 1.1) (Figure 1.2). 
Aqueous humor is produced by the ciliary body which involves the blood flow to the 
ciliary processes, ultrafiltration of plasma in tissue spaces of ciliary processes and 
secretion by ciliary epithelium (Brubaker, 1991). Then, it flows from the ciliary epithelium 
into the posterior chamber and then through the pupil into the anterior chamber. 
Subsequently, it flows out through the trabecular meshwork-Schlemm’s canal or the 
uveoscleral outflow pathway to the systemic circulation. The elevated pressure in the 
eye as mentioned above, results in progressive changes in the optic nerve head and 
retina where it involves the axonal and non-axonal effects and retinal ganglion cells 
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appeared to undergo changes in neurotrophin response prior to cell death respectively 
(Morrison et al., 2005). Thus, it may influence the relative susceptibility to IOP and 
explain the progressive optic nerve damage and visual field loss. 
 
1.1.1 Prevalence of glaucoma 
 
Primary open angle glaucoma (POAG) is one of the leading causes of irreversible visual 
loss in Western countries with the prevalence of 1.1% to 3.0% (Dielemans et al., 1994). 
Based on an extensive systemic review of 111 published reports by Quigley (1996) on 
the prevalence of glaucoma, 66.8 million was estimated to have primary glaucoma, with 
6.7 million suffering from bilateral blindness. Another report by Quigley in 2002 
estimated that people suffering from bilateral blindness by OAG and ACG will be 
increased to 7.6 million. It is estimated that 60.5 million people will suffer from OAG and 
ACG by 2010, increasing to 79.6 million people by 2020, 74% of them will have OAG 
and Asians will represent 47% of those who having glaucoma (Quigley and Broman, 
2006). Similarly, 4.5 million people with OAG and 3.9 million people with ACG is 
estimated to develop bilateral blindness in 2010, further increased to 5.9 and 5.3 million 
people in 2020 respectively (Quigley and Broman, 2006). Thus, without doubt, glaucoma 
has emerged as the second leading cause of blindness worldwide, after cataract 
(Quigley and Broman, 2006). 
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Figure 1.1: The drainage of aqueous humor either by conventional outflow pathway 
(Trabecular meshwork-Schlemm’s canal) or non-conventional outflow (uveoscleral 
outflow). Adapted from: http://www.unmc.edu/dept/physiology/index.cfm 
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Figure 1.2: Elevated intraocular pressure ultimately will cause damage to the optic nerve 
at the back of the eye. Adapted from: http://www.theeyefoundation.com/glaucoma.htm 
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In Singapore, based on population-based cross-sectional study, glaucoma was found as 
a leading cause of blindness among Singaporean Chinese adults which contributed to 
60.0% of bilateral blindness, with the age and gender-adjusted prevalence rates being 
1.1% and 0.5% for bilateral low vision and bilateral blindness respectively (Saw et al., 
2004). Similar population-based cross-sectional study conducted in Thailand, showed 
that glaucoma was the second most common cause of severe unilateral visual loss. 
Primary open angle glaucoma (POAG) accounted for 67% of all glaucoma (Bourne et 
al., 2003). They also reported that 11% of the bilateral blindness was caused by 
glaucoma. In Malaysia, a National Eye Survey conducted in 1996, found that cataract 
was still the leading cause of blindness (39%) followed by retinal disease (24%), 
uncorrected refractive error and corneal disease. Glaucoma was only ranked fifth as the 
major cause of blindness (1.8%) (Zainal et al., 2002), which was mainly due to high 
percentage of underestimation on the prevalence of glaucoma. However, the 
examination was conducted by using only direct ophthalmoscope and torch light without 
proper glaucoma diagnostic tools such as tonometer, gonioscopy and visual field 
assessment. 
 
In general, the risk of blindness from glaucoma is very high among patients in the 
developing countries (Chen, 2004). Late presentation was found as the major cause of 
blindness in 29% to 41% of glaucoma patients (Kwon et al., 2001, Oliver et al., 2002, 
Chieng et al., 2005). Poor awareness of the disease is closely related to the late 
presentation. Famously known as the silent thief of vision, OAG is asymptomatic, patient 
only become aware once the disease is in advanced stage. According to Hugh Taylor 
and Jill Keeffe (2001), at least half of people with glaucoma were under diagnosed and 
consequently, not treated. In spite of better awareness, the problems are not better in 
the developed countries. A survey on German population revealed that 75% of the 
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respondents have heard about glaucoma but only 8% correctly defined glaucoma 
(Pfeiffer et al., 2002). Almost similar findings were also reported from Hong Kong with 
fewer numbers even aware of the mode of treatment which include drugs, laser and 
surgery (Lau et al., 2002).  
 
1.1.2 Management of glaucoma  
 
Management of glaucoma ranges from the safest and the least invasive method to those 
that expose the patients to greater risk and are more invasive. Basically, glaucoma 
therapy involves medical therapy, laser treatment and filtrating surgery (trabeculectomy), 
which aim at the reduction of IOP; the only modifiable risk factors. Till now IOP is the 
only manipulative tool to prevent further nerve fiber damage as has been shown by 
several large, randomized control trials, where lowering the IOP has been associated 
with the retardation of progressive optic nerve damage (Morrison et al., 1998, Heijl et al., 
2002, Leske et al., 2003).  
 
The goal of antiglaucoma therapy is the achievement of a targeted intraocular pressure. 
Target pressure is defined as the mean of an estimated IOP with treatment that is 
expected to prevent further glaucomatous damage (Spaeth, 2000) or as the level of 
intraocular pressure which is associated with minimal likelihood of visual field or optic 
nerve lesion or an existing lesion progression due to elevated intraocular pressure 
(Popovic-Suic et al., 2005). For example, glaucoma therapy in ocular hypertension 
patients should at least achieve 20% IOP reduction from baseline in those with moderate 
to high risk glaucoma, based on perimetric changes; IOP should be lowered by at least 
30% in early to moderate glaucoma and 40% to 50% in severe glaucoma (Schwartz and 
Budenz, 2004). An additional 15% of IOP reduction is targeted if there is evidence of 
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visual field progression (American Academy of Ophthalmology Preferred Practice 
Patterns Committee Glaucoma Panel, 2001). Several randomized clinical trials such as 
Collaborative Normal Tension Glaucoma Study (CNTGS), Advanced Glaucoma 
Intervention Study (AGIS), Collaborative Initial Glaucoma Study (CIGS), Ocular 
Hypertension Treatment Study (OHTS) and Early Manifest Glaucoma Treatment Study 
(EMGTS) provided evidence that above cited parameters may be useful towards the 
setting of initial IOP goal in glaucoma patients (Heijl et al., 2002, Anderson, 2003, Feiner 
and Piltz-Seymour, 2003, Nouri-Mahdavi et al., 2004, Kymes et al., 2006). All these 
studies concluded that IOP reduction is very essential in preventing further progression 
of glaucoma.  
 
Though there are a few options for management of IOP in glaucoma but medical 
treatment, mainly using topical antiglaucoma drugs, still remains the first line 
management of glaucoma as it is non invasive method and easy to administer. In 
addition, patients’ compliance with medication regimen is also critical in evaluating the 
effectiveness of treatment. The instillation of topical antiglaucoma drugs which is easy, 
will improve a patient’s compliance. Ocular hypotensive effects are induced by a topical 
antiglaucoma drug either by reducing the production of aqueous humor or by increasing 
the outflow of aqueous. 
 
Before the emergence of prostaglandin derivatives as ocular hypotensive agents, there 
were several classes of medications available. Currently, there are at least five different 
classes of anti-glaucoma agents including beta blocker (timoptol, betaxolol), 
parasympathetic agonist (pilocarpine), carbonic anhydrase inhibitor (dorzolamide, 
brinzolamide), adrenergic agonists (propine, adrenaline) and alpha 2 agonist 
(brimonidine). Prostaglandin analogues like latanoprost, travaprost and bimatoprost are 
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other newly discovered class of ocular hypotensive agents. So far, only latanoprost has 
been approved for first line therapy (Physicians Desk Reference for Ophthalmic 
Medicines, 2003).  
 
1.2 Latanoprost 
 
1.2.1 Background 
 
Management of glaucoma was rather difficult before 1995, since only five groups of 
topical antiglaucoma medications were available, namely cholinergic agonist, 
parasympathetic agonist, beta-blockers, alpha-2 agonist and carbonic anhydrase 
inhibitors. Significant efforts and advances have been achieved later in the development 
of topical antiglaucoma medications. Since the introduction of latanoprost in 1996, 
prostaglandin analogues had emerged as one of the most prescribed antiglaucoma 
medication among the ophthalmologists. Prostaglandin analogues (latanoprost, 
bimatoprost and travoprost) are the most potent pressure lowering agents (Alexander et 
al., 2002). The prostaglandin analogues (bimatoprost 0.03% and travoprost 0.004%) 
were proven to be more effective in lowering the IOP than the previous first-line agent, 
timolol 0.5% (Netland et al., 2001, Sherwood and Brandt, 2001).   
 
Prostaglandins are autacoids lipid derivative generated by metabolism of arachidonic 
acid by the cyclooxygenase (COX) and prostaglandin synthase enzymes (Hata and 
Breyer, 2004). Prostaglandins modulate many of the physiological systems including the 
CNS, cardiovascular, endocrine, respiratory and immune systems. It is also generally 
considered to be a potent pro-inflammatory mediator (Hata and Breyer, 2004). The 
expression of one of the COX enzyme, COX-2, mainly depends on the response to 
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inflammatory cytokines and bacterial lipopolysaccharide (Masferrer and Kulkarni, 1997, 
Hata and Breyer, 2004). Therefore, those prostaglandins that are generated via COX-2 
are responsible for the inflammatory effects. Studies also demonstrated that there was a 
significant increase in prostaglandin in aqueous humor and tear fluid in clinical ocular 
inflammatory conditions and diseases (Kulkarni and Mancino, 1993, Hata and Breyer, 
1997). The production of inflammatory prostaglandin in ocular tissues also resulted from 
the COX-2 expression since this enzyme plays a major role in the production of 
prostaglandin in the inflammatory cascade. 
 
Topical latanoprost 0.005% (Xalatan, Pfizer), PGF2α analogue, a selective agonist of the 
FP receptor, is well tolerated and has become one of the most commonly used drug to 
treat glaucoma and ocular hypertension (Alm, 1998). Latanoprost (code name PhXA41; 
13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2α-isopropyl ester) is a prodrug with a 
phenyl ring substituted for carbon 18-20 in the omega chain and it have a saturated 
double bond between carbons 13 and 14 (Stjernschantz and Resul, 1992) (Figure 1.3). 
It is rapidly hydrolysed in the cornea and blood to its primary metabolite, latanoprost acid 
following topical instillation into the eye (Sjoquist and Stjernschantz, 2002).  
 
In spite of an excellent pressure lowering agent, the exact mechanism of action of 
latanoprost is not really established. It is believed that ocular hypotensive effect is 
achieved by increasing the aqueous humor outflow through both the trabecular route (via 
Schlemm’s canal and episcleral veins) and the uveoscleral (ciliary muscle) pathway. The 
precise mechanism of prostaglandin analogues in achieving pressure lowering effect 
had created various postulations and debates. One of the well accepted postulations is 
PGF2α analogue reduces the IOP by increasing the uveoscleral outflow of aqueous  
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Figure 1.3: Chemical structures of latanoprost which consists of two long carbon chains 
(alpha and omega). Adapted from: http://www.chem-online.org/generic-
pharmaceutical/latanoprost.htm 
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humor possibly by reducing the resistance between the ciliary muscles, through the 
effect on the extracellular matrix (ECM) (Kunapuli et al., 1997).  
 
Matrix metalloproteinase (MMP) is a family of neutral, zinc-dependent enzymes that can 
hydrolyze specific peptide sequences found in ECM structural proteins (Birkedal-Hansen 
et al., 1993). There is evidence that exposure to PGF2α, 11-deoxy-PGE1 or latanoprost 
acid (the active form of latanoprost), increased the secretion of MMP-1, MMP-2, MMP-3 
and MMP-9 by human ciliary smooth muscle cells (Weinreb et al., 1997). For example, 
MMP-1 efficiently targets a specific site found in the fibrillar collagen types I and III. 
MMP-3 efficiently cleaves specific sites found in collagen types IV, IX, XI as well as in 
fibronectin and aggrecan core protein. MMP-2 cleaves sites in collagen IV, V, VII and X. 
MMP-9 cleaves sites in collagen IV and V. Hence, these MMPs may lead to alterations 
of numerous ECM components within the ciliary muscle (Weinreb et al., 1997, Ocklind, 
1998, Weinreb et al., 2002). 
 
The reduction of ciliary muscle ECM within the extracellular spaces among the ciliary 
muscle fiber bundles where aqueous humor passes through the uveoscleral outflow, 
could reduce the hydrolic resistance to aqueous movement and increases the 
uveoscleral outflow (Lindsey et al., 1997, Weinreb et al., 2002) (Figure 1.4). Another 
report suggested that PGF2α induced vasodilation in the ciliary body, and enhances the 
uveoscleral outflow by tissue expansion (Bill, 1989). 
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Whatever the postulations, the evidence concentrate on relaxation of the ciliary muscle 
as the most likely mechanism of latanoprost-enhanced uveoscleral outflow. However, 
the prostanoid FP receptor needs to couple to Gq protein in order to activate the 
phospholipase C, IP3 generation and calcium mobilization, which is associated with 
contraction of smooth muscle (Coleman et al., 1994). 
 
1.2.2 Intraocular Pressure (IOP) Lowering Effect of Latanoprost 
 
1.2.2.1 Latanoprost as monotherapy treatment 
 
Latanoprost has been proven to be effective in reducing the IOP either as a 
monotherapy or adjunctive therapy in patients who failed to achieve desirable IOP with 
their current glaucoma treatment regimen (Rulo et al., 1994, Alm and Stjernschantz, 
1995, Mishima et al., 1996, Aquino and Lat-Luna, 1999, O’Donoghue, 2000, Bron et al., 
2001). In addition, many randomized clinical trials conducted on patients with open-
angle or ocular hypertension, revealed that monotherapy with latanoprost reduces IOP 
levels by 20% to 40% at 1 and 12 months of treatment (Alm and Stjernschantz, 1995, 
Camras et al., 1996, Mishima et al., 1996, Watson and Stjernschantz, 1996, Aquino and 
Lat-Luna, 1999). The maximum ocular hypotensive effect can be achieved within 8 to 12 
hours after instillation of once daily topical dose of latanoprost 0.005% to both healthy 
individuals and open-angle glaucoma and ocular hypertension patients in Japan and 
Europe (Hotehama et al., 1993, Racz et al., 1996, Mishima et al., 1997). In addition, 
latanoprost was also found to be able to provide uniform circadian (around-the-clock) 
IOP reduction (Racz et al., 1996). The magnitude of IOP reduction was found to be 
essentially identical during both daytime and nighttime hours (Mishima et al., 1997). 
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1.2.2.2 Comparison with other topical antiglaucoma drugs as monotherapy 
 
Latanoprost has proven to be more effective in reducing the IOP when compared to 
other classes of topical antiglaucoma drugs such as beta blocker (timolol), carbonic 
anhydrase inhibitor (dorzolamide) and alpha-2 agonist (brimonidine) as monotherapy 
treatment (Camras, 1996, Einarson et al., 2000, O’Donoghue, 2000). Latanoprost 
0.005% once daily was significantly more effective than timolol 0.5% twice daily at 3 to 6 
months of treatment (Alm and Stjernschantz, 1995, Camras et al., 1996, Mishima et al., 
1996, Aquino and Lat-Luna, 1999). It reduces mean baseline diurnal IOP by 6.2 to 11.1 
mmHg (27% to 39%) compared to 4.4 to 9.1 mmHg reduction by topical timolol (19% to 
33%). The pressure lowering effect of latanoprost is not only greater but more consistent 
at daytime and nighttime compared to timolol (Larsson, 2001). A randomized crossover 
trial studies on latanoprost and timolol found significantly greater mean IOP reduction 
both during daytime and nighttime hours with latanoprost (p < 0.001) (Orzalesi et al., 
2000, Larsson, 2001).  
 
Latanoprost 0.005% once daily was also found to be significantly effective than 
dorzolamide 2% three times daily (O’Donoghue, 2000). A meta analysis involving nine 
comparative studies on glaucoma patients who received latanoprost and brimonidine, 
showed latanoprost providing a greater IOP reduction compared to brimonidine after 3 
months (33% to 26% of IOP reduction by brimonidine) and 6 months of treatment (32% 
to 25% of IOP reduction by brimonidine) (Einarson et al., 2000). In spite of various 
evidences of better IOP lowering effect, several randomized clinical trials found that 
latanoprost 0.005% have no clinically significant difference in the ability of IOP-lowering 
effect at 8.00 am, the time of peak effect with bimatoprost 0.03% or travoprost 0.004% 
(Gandolfi et al., 2001, Netland et al., 2001, Walters et al., 2001, Parrish et al., 2003). 
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However, Parrish et al., (2003) who conducted a 12-week, randomized, masked-
evaluator, multi-center study on patients with open-angle glaucoma and ocular 
hypertension on once daily treatment with latanoprost 0.005%, bimatoprost 0.03% and 
travoprost 0.004% and found that baseline mean 8.00 am IOP were similar among the 
treatment groups with significant reduction from baseline with each treatment after 12 
weeks. This 12 weeks study demonstrated that latanoprost, bimatoprost and travoprost 
are equally potent IOP lowering agents that are generally well tolerated systemically.  
 
1.2.2.3 Adjunctive therapy 
 
Latanoprost is well known to be an effective pressure lowering agent either as 
monotherapy or adjunctive therapy compared to the other classes of antiglaucoma 
drugs. A study conducted in France found that there was a good effect on IOP reduction 
achieved when adding latanoprost to timolol in patients with inadequate IOP control with 
timolol in open angle glaucoma or ocular hypertension (Bron et al., 2001). It also proved 
to be a good IOP lowering agent compared to the other classes of antiglaucoma drugs 
when used as adjunctive therapy to timolol. There was similar findings found by Italian 
and German Latanoprost Study Group where greater IOP reduction in diurnal IOP was 
achieved after adding latanoprost compared to pilocarpine in patients whom IOP was 
inadequately controlled with timolol alone (Bucci, 1999, Diestelhorst, 2000). The IOP 
lowering effect of latanoprost also was found to be superior to dorzolamide and 
brimonidine when added to patients who was previously treated with timolol (Petounis et 
al., 2001, Simmons and Earl, 2002).  
 
Rulo et al., (1997) found that the mean IOP of patients with elevated IOP treated with 
acetazolamide was further reduced after topical administration of latanoprost. In a 
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preliminary study involving untreated ocular hypertensive patients who was initially 
treated with 2% pilocarpine three times a day for three days, achieved further additional 
IOP reduction with topical latanoprost (Villumsen and Alm, 1992). In addition, another 
study demonstrated the reduction of IOP by an additional 14% after latanoprost was 
added to pilocarpine in patients with elevated IOP (Fristrom and Nilsson, 1993).   
 
1.2.2.4 Latanoprost non-responder 
 
Even though latanoprost has been regarded as a powerful IOP lowering agent, there are 
patients who demonstrated failure to achieve IOP reduction, also known as non-
responders. The reported incidence of latanoprost non responders ranged from 12% to 
41% in American and European population (DuBiner et al., 2001, Scherer, 2002, 
Williams, 2002). However, the definition of non-responders which varies from one study 
to another, lead to difficult in truly assessing the response. For example, Scherer, (2002) 
defined the non responders as patients who achieved IOP reduction less than 20% of 
baseline or reduction of less than 5 mmHg (Scherer, 2002). While Williams, (2002), 
categorized patients with IOP reduction of less than 3 mmHg after 4 weeks of treatment 
as non responders and DuBiner et al., (2001) defined it as less than 20% IOP reduction 
at 3 months past treatment. Noecker et al., (2003) compared the IOP lowering efficacy 
and safety of topical bimatoprost 0.03% with latanoprost 0.005% found that 17.6% to 
25% of patients who was treated with latanoprost achieved less than 15% IOP reduction. 
Netland et al., (2001) defined non responder as those who achieved less than 3 mmHg 
of IOP reduction at 20 hours after dose and found that 13.5% non responder rate in their 
study. Ikeda et al., (2006) investigated the incidence and clinical profiles of latanoprost 
non responders in Japanese population and found that after 12 months of treatment, the 
incidence of latanoprost non responders was 31.8%, which higher than American and 
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European patients. A study conducted by Aung et al., (2001), compared the intraocular 
pressure lowering effect and side effect of latanoprost 0.005% with unoprostone 0.12% 
among Singaporean patients with POAG and ocular hypertension found that 10.3% to 
14.8% of patients show less than 15% of IOP reduction from baseline. 
 
A big question for such variation of response to latanoprost still remains. Ikeda et al., 
(2006) postulated that the delivery of inadequate concentrations of the drug to the 
intraocular system may contribute to the high rate of latanoprost non responder (Ikeda et 
al., 2006). Racial differences and ethnic background is thought to play a role in the 
differences of response among various populations. Some even postulated that the 
differences of pigmentation of iris, hair and dermis among population may also 
contribute to the rate of latanoprost non responder (Netland et al., 2001, Ikeda et al., 
2006). Genetic factors were also postulated to be involved and play a role in the 
variation of responsiveness to latanoprost (Ikeda et al., 2006).  
 
1.2.3 Adverse Effects of Latanoprost 
 
1.2.3.1 Conjunctival hyperemia  
 
Even though it has been proven to be a good drug in reducing IOP, adverse effects such 
as hyperemia and iris pigmentation were reported (Patel and Spencer, 1996, Alm et al., 
1997). Most of the adverse events are mild and reversible when treatment is 
discontinued. One of the most common side effects of latanoprost is conjunctival 
hyperemia (Racz et al., 1993, Alm et al., 1995, Camras, 1996). This adverse effect could 
become a concerning issue among the ophthalmologists because it may compromise 
the outcome of filtration surgery and may represent a cosmetic problem to the patients 
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leading to non-compliance (Feldman, 2003). Studies conducted in Scandinavia, United 
Kingdom and United States of America reported that 4%, 15% and 5% respectively of 
the occurrence of mild conjunctival hyperemia as ocular side effect on latanoprost 
treatment (Alm et al., 1997). The incidence of ocular adverse events in short term trials 
are almost similar between latanoprost and bimatoprost (DuBiner et al., 2001). However, 
in another study by Gandolfi et al., (2001), bimatoprost and travoprost shows 
substantially higher rates of ocular adverse reactions especially conjunctival hyperemia. 
According to Zhang et al., (2001), the risk for developing hyperemia after receiving 
latanoprost treatment was over twice that seen in timolol.  
 
The development of conjunctival hyperemia is believed to be due to secondary, 
unrelated mechanism (Feldman, 2003). In fact, variation in the incidence of conjunctival 
hyperemia is believed to occur due to the differences in chemical structures of 
prostaglandin derivatives (Feldman, 2003). The molecular structure of other 
prostaglandin analogues such as travoprost and bimatoprost differ from latanoprost, with 
the presence of saturated double bond at the C13-C14 position of the molecule. The 
double bond at this particular position is believed to enhance the occurrence of 
conjunctival hyperemia as the adverse effect (Stjernschantz, 2001). Resul and 
Stjernschantz, (1993) proposed another theory, that this could be caused by a 
vasodilation related to the release of nitric oxide resulting from the excessive production 
of nitric oxide synthase induced by prostaglandin analogues (Resul and Stjernschantz, 
1993). However, the precise mechanism on the release of nitric oxide remains unknown 
(Astin et al., 1994, Stewart et al., 2003).    
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1.2.3.2 Iris hyperpigmentation 
 
Iris hyperpigmentation has been one of the most intriguing adverse effects of 
latanoprost. Latanoprost has been reported to induce iris hyperpigmentation in humans 
and monkeys (Alm et al., 1997, Selen et al., 1997, Albert et al., 2000). The iridial 
pigment changes as well as periocular skin pigmentation and eyelash hypertrichosis, 
later were regarded as the side effect of latanoprost and other prostaglandin analogues 
in various clinical studies (Alm and Stjernschantz, 1995, Camras, 1996, Watson and 
Stjernschantz, 1996, Netland et al., 2001, Parrish et al., 2003). In human, increase in iris 
hyperpigmentation was reported to be 5 to 15% of the patients who were treated with 
topical latanoprost where the highest number of cases occurring in patients with ‘hazel’ 
or heterochromatic eye colour (Wistrand et al., 1997). In contrast, Alm et al., (1995) 
reported that incidence was found to be as high as 69.7% with higher risk in irides of 
mixed colour than in blue, grey or brown irides. In addition, a retrospective study 
conducted in Japan revealed that 42% of patients had increased iris hyperpigmentation 
induced by latanoprost after 12-month follow-up (Hara, 2001). On the other hand, Chiba 
et al., (2004) conducted a prospective study of iridial pigmentation as a result of 
treatment with latanoprost and found that there was definite increase in iridial 
pigmentation after 6-months and 12-months of treatment. 
 
The precise mechanism of prostaglandin-induced iris hyperpigmentation (PIIP) remains 
to be elucidated. Among the possible mechanisms that have been focused by many of 
the researchers include the regulation of melanogenesis processes such as the enzyme 
tyrosinase which is involved in the synthesis of melanin, production of PGE2 or 
sympathetic system innervation (Drago et al., 1999, Dutkiewicz et al., 2000, Hu et al., 
2000, Stjernschantz, 2001). Latanoprost was found to induce the melanin production 
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which involved the tyrosinase activity via a non-cAMP-dependent pathway (Hu et al., 
2000). It was also found to affect tyrosinase at the gene transcription level in iridial 
melanocytes as observed in treated and control cynomolgus monkeys (Stjernschantz et 
al., 2000).  
 
It is also postulated that latanoprost possess a potential to exert a melanogenic effect via 
a melanocytic FP receptors (Ocklind et al., 1996). While unoprostone, the other 
prostaglandin analogue with low affinity for the FP receptor, enhances the tyrosine 
activity, which was also found to be associated with the increase of iris 
hyperpigmentation in clinical trials (Chiba et al., 2003, Zhan et al., 2003). This evidence 
may suggest that the stimulation of FP receptor in melanogenesis is questionable. On 
the other hand, latanoprost was also found to be consistently inducing the in vitro 
production of PGE2 in iridial melanocytes (Stjernschantz, 2001). In another study, 
increased melanogenesis in cultured iridial melanocytes was also found to be coincided 
with increased PGE2 production (Bergh et al., 2002). The increase of PGE2 production in 
melanogenesis may be mediated by cyclooxygenase-2 enzyme (Bhattacharya et al., 
1998). 
 
1.2.3.3 Hypertrichosis 
 
Recently, latanoprost has been recognized as a drug which is capable of inducing 
hypertrichosis involving eyelashes, adjacent adnexal hair and vellus hair of the skin 
(Johnstone, 1997, Wand, 1997). Latanoprost treatment was found to increase thickness, 
length and curvature of the lashes as well as resulted in full growth of eyelashes in a 
patient with previous loss of eyelashes due to alopecia (Johnstone, 1998, Mansberger 
and Cioffi, 2000). Glaucoma patients who were treated with latanoprost unilaterally, 
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showed evidence of hypertrichosis in the treated eye (Johnstone, 1997). However, 
latanoprost-induced eyelash hypertrichosis was also found to be reversed at 8 months 
after the medication was discontinued (O’Toole et al., 2001). 
 
To date, the mechanism by which latanoprost causes eyelash hypertrichosis is still not 
fully understood. Prostaglandins are important stimulants of melanogenesis and the FP 
receptor which latanoprost binds has been localized in majority of ocular tissues as well 
as the hair follicle (Woodward et al., 1997, Stjernschantz, 2001). The pigmented 
melanosomes in the bulb of hair follicle also can be transferred to hair keratinocytes 
(Wand, 1997). 
 
1.2.3.4 Other side effects of latanoprost 
 
Red eye or conjunctival hyperemia is another important side effect of latanoprost. Since 
prostaglandins are mediators of topical inflammation in the eye, it is not surprising the 
synthetic prostaglandins or ocular hypotensive lipids induce inflammatory processes or 
cause irritating reactions. Compared to other prostaglandin analogue, latanoprost 
appeared to be the least reported ocular irritation (Larsson, 2001). In addition, cystoid 
macular edema (CME) was also reported in several cases (Miyake et al., 1999, Netland 
et al., 2001). However, there was no study that was able to estimate the risk of 
developing cystoid macular edema after administration of latanoprost. The risk appears 
to be increased if the natural lens is missing or the posterior capsule of the eye is 
destructed. However, latanoprost induced cystoid macular edema is a transient effect, 
which resolve after discontinuation of the treatment (Larsson et al., 2002).  
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In contrast to topical timolol, systemic adverse reactions are infrequent with latanoprost 
therapy, perhaps due to the fast degradation of prostaglandin (Patel and Spencer, 
1996). It is due to the presence of enzymes which degrade the naturally occurring 
prostaglandins not far from the site that they are produced. Clinical studies of latanoprost 
also found no significant effects on peak expiratory flow, forced expiratory volume in one 
second, forced ventilatory capacity, asthma symptoms or asthma medication 
requirements (Hedner et al., 1999, Waldock et al., 2000). Even though there are several 
adverse reactions of latanoprost, but not all the patients will experience all the side 
effects. The postulation is that the effectiveness of the drugs varies according to 
individuals, and could be attributed to any changes in the receptor which may be 
responsible for the variation of effectiveness of the drug as well as the adverse reaction. 
Variations in the gene coding for the receptors are therefore believed to be also 
responsible for the variations in the receptors. This branch of science that deals with the 
relation of genetic factors to variation in response to drugs is called pharmacogenetics. 
 
1.3 Pharmacogenetics  
 
The word pharmacogenetics which usually has been used interchangeably with 
pharmacogenomics can be defined as the study of the impact of genetic variation on the 
efficacy and toxicity of drugs, or the study of how genetic makeup determines the 
response to a therapeutic intervention (Zilfalil, 2005). The development of 
pharmacogenetics over the years remained slow since family studies were difficult and a 
direct DNA study was not yet possible (Motulsky and Qi, 2006). Pharmacogenetics also 
suffered from the lack of integration into clinical practice. There were several reasons 
mainly due to unmet need for education at medical schools and the lack of awareness 
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about the impact of genetic medicine on healthcare in the community (Frueh and 
Gurwitz, 2004).  
 
Inter-individual variability of drug response poses a major problem in clinical practice 
with some patients do not response favorably or suffered severe adverse drug reactions. 
A meta-analysis of 39 prospective studies from United States hospitals suggests that 
adverse drug reactions are responsible for about 2.2 million hospitalizations and 100,000 
deaths per year (Lazarou et al., 1998). The high frequencies of adverse drug reactions 
cases and its association with high mortality and morbidity rates are now becoming a 
major health policy concern worldwide.  
 
Pharmacogenetic studies have shown that polymorphisms of drug metabolizing 
enzymes, transporters and receptors contribute to variable drug response (Evans and 
Relling, 1999, Evans and Johnson, 2001). There were also numerous other factors that 
contribute to variable drug response including age, sex, body weight, nutrition, organ 
function, infections and co-medications. Although these non-genetic factors can be very 
important, but the inherited differences in the metabolism and disposition of drugs, and 
genetic polymorphisms in the targets of drug therapy (receptors) and drug transporter 
can have a major influence on the efficacy and toxicity of many medications. For 
example, the missense mutation and polymorphic CAG microsatellite in the gene 
encoding androgen receptor has reversed its effect and contribute its failure to response 
to antiandrogenic therapy that usually used in the therapy of prostate cancer 
(Schoenberg et al., 1994). Single nucleotide polymorphisms resulted in changes of the 
amino acids 16 and 27 of the beta2-adrenergic receptor found to alter the 
responsiveness of anti-asthmatic chemotherapy among the asthmatic patients (Drysdale 
et al., 2000). 
